$MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ร agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Healthcare
Sector
Biotechnology
Industry
William J. Sibold
CEO
528
Employees
$454.22
Current Price
$10.55B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 5 | 17 | $2,626,261.97 | 6,098 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 5 | 21 | $4,170,743.15 | 9,232 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 6 | 83 | $28,325,956.12 | 55,612 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 646 | $431.94 | $279,033.24 | View Details |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 40 | $425.08 | $17,003.20 | View Details |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 420 | $426.86 | $179,282.80 | View Details |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 80 | $427.85 | $34,227.60 | View Details |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 160 | $429.00 | $68,639.20 | View Details |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 40 | $429.58 | $17,183.20 | View Details |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 120 | $430.90 | $51,708.40 | View Details |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 116 | $432.56 | $50,176.48 | View Details |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 160 | $434.20 | $69,472.00 | View Details |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 80 | $435.31 | $34,825.20 | View Details |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 80 | $436.69 | $34,935.20 | View Details |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 40 | $437.65 | $17,506.00 | View Details |
| Mar 6, 2026 | Sibold William John Director | Sale | 1,663 | $431.94 | $718,316.22 | View Details |
| Mar 6, 2026 | Kelley Shannon T General Counsel | Sale | 360 | $431.94 | $155,498.40 | View Details |
| Mar 6, 2026 | Huntsman Carole Chief Commercial Officer | Sale | 419 | $431.94 | $180,982.86 | View Details |
| Mar 6, 2026 | Taub Rebecca Director | Sale | 491 | $431.94 | $212,082.54 | View Details |
| Mar 2, 2026 | Dier Mardi EVP and CFO | Sale | 1,183 | $427.21 | $505,389.43 | View Details |
| Jan 26, 2026 | Huntsman Carole Chief Commercial Officer | Sale | 570 | $494.59 | $281,916.30 | View Details |
| Jan 26, 2026 | Huntsman Carole Chief Commercial Officer | Sale | 340 | $492.42 | $167,422.80 | View Details |
| Jan 26, 2026 | Sibold William John Director | Sale | 1,577 | $492.42 | $776,546.34 | View Details |
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated$0.01
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated$0.04
ActualN/A
Revenue
Estimated$312.74M
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies:
$KOD โ Kodiak Sciences Inc.via BAKER BROS. ADVISORS LP$CELC โ Celcuity Inc.via BAKER BROS. ADVISORS LP$IMCR โ Immunocore Holdings plcvia BAKER BROS. ADVISORS LP$TRDA โ Entrada Therapeutics, Inc.via BAKER BROS. ADVISORS LP$DNLI โ Denali Therapeutics Inc.via BAKER BROS. ADVISORS LP$KYMR โ Kymera Therapeutics, Inc.via BAKER BROS. ADVISORS LP